The prognostic efficacy of cell-free DNA hypermethylation in   colorectal cancer

Simon Ladefoged Rasmussen; Henrik Bygum Krarup; Kåre Gotschalck Sunesen; Martin Berg Johansen; Mogens Tornby Stender; Inge Søkilde Pedersen; Poul Henning Madsen; Ole Thorlacius-Ussing

doi:10.18632/oncotarget.24097

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer

Simon Ladefoged Rasmussen _, Henrik Bygum Krarup, Kåre Gotschalck Sunesen, Martin Berg Johansen, Mogens Tornby Stender, Inge Søkilde Pedersen, Poul Henning Madsen and Ole Thorlacius-Ussing

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:7010-7022. https://doi.org/10.18632/oncotarget.24097

Metrics: PDF 1333 views | HTML 2041 views | ?

Abstract

Simon Ladefoged Rasmussen1,2,3, Henrik Bygum Krarup2,4, Kåre Gotschalck Sunesen1, Martin Berg Johansen5, Mogens Tornby Stender1, Inge Søkilde Pedersen2,4, Poul Henning Madsen2,4 and Ole Thorlacius-Ussing1,2,3

1Department of Gastrointestinal Surgery, Aalborg University Hospital, Aalborg, Denmark

2Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark

3Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

4Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark

5Unit of Clinical Biostatistics, Aalborg University Hospital, Aalborg, Denmark

Correspondence to:

Simon Ladefoged Rasmussen, email: [email protected]

Keywords: colorectal cancer; DNA hypermethylation; prognosis; staging

Received: September 08, 2017 Accepted: January 03, 2018 Published: January 09, 2018

ABSTRACT

Epigenetic alterations in colorectal cancer (CRC) cause important differences in the underlying tumor biology and aggressiveness. DNA hypermethylation is central for the development of CRC but the prognostic impact remains elusive. We aimed to assess the association between cell-free hypermethylated DNA and stage and survival in colorectal cancer (CRC).

We analyzed pre-treatment plasma samples from 193 patients with CRC. Thirty gene-promoter regions were analyzed using methylation specific PCR. We compared the median number (range) of hypermethylated promoter regions with CRC stage, and constructed a multivariable Cox-regression model adjusted for stage, to evaluate the added prognostic information.

The median number of hypermethylated promoter regions was nine (0-28) in patients with distant metastasis compared to five (0-19) in patients without metastatic disease (p < 0.0001). The majority of the hypermethylated promoter regions inferred a poor prognosis. Cox-regression analysis adjusted for patient age, sex, pre-treatment CEA-levels, and disease stage, showed that RARB (HR = 1.99, 95% CI [1.07, 3.72]) and RASSF1A (HR = 3.35, 95% CI [1.76, 6.38]) hypermethylation inferred a significant effect on survival.

The risk of metastasis increase with the number of cell-free hypermethylated promoter regions. The presence of RARB and RASSF1A hypermethylation indicated aggressive disease, regardless of stage at the time of diagnosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24097

Publication Alerts

Research Papers:

The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer

Abstract